Cefpodoxim

# Cefpodoxim ## Overview - **Classification**: Third-generation cephalosporin antibiotic - **Mechanism**: Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. ## Primary Indications 1. **Acute Otitis Media (AOM)** - Bacterial ear infection. 2. **Pharyngitis/Tonsillitis** - Bacterial throat infection. 3. **Community-Acquired Pneumonia (CAP)** - Bacterial lung infection. 4. **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)** - Worsening of chronic bronchitis. 5. **Uncomplicated Urinary Tract Infections (UTI)** - Bacterial infection of the urinary tract. 6. **Uncomplicated Skin and Skin Structure Infections** - Bacterial skin infections. ## Adult Dosing ### Standard Dosing **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)** - **Dose**: **200 mg** - **Frequency**: Every 12 hours - **Route**: Oral - **Duration**: 10 days **Community-Acquired Pneumonia (CAP)** - **Dose**: **200 mg** - **Frequency**: Every 12 hours - **Route**: Oral - **Duration**: 14 days **Pharyngitis/Tonsillitis** - **Dose**: **100 mg** - **Frequency**: Every 12 hours - **Route**: Oral - **Duration**: 5-10 days **Uncomplicated Urinary Tract Infections (UTI)** - **Dose**: **100 mg** - **Frequency**: Every 12 hours - **Route**: Oral - **Duration**: 7 days **Uncomplicated Skin and Skin Structure Infections** - **Dose**: **400 mg** - **Frequency**: Every 12 hours - **Route**: Oral - **Duration**: 7-14 days ### Dose Adjustments - **Renal Impairment**: - CrCl 10-30 mL/min: Administer standard dose every **24 hours**. - CrCl < 10 mL/min: Administer standard dose every **48 hours**. - Hemodialysis: Administer dose after dialysis (3 times/week dosing). - **Hepatic Impairment**: No specific dose adjustment necessary. - **Elderly Patients**: Dose adjustments based on renal function, not age. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not generally recommended due to limited data. - **Special Notes**: Consult with a pediatric infectious disease specialist. ### Infants (1-12 months) - **Acute Otitis Media (AOM)**: - **Dose**: **5 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: **200 mg** per dose (400 mg daily) - **Pharyngitis/Tonsillitis**: - **Dose**: **5 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: **100 mg** per dose (200 mg daily) - **Special Notes**: Oral suspension formulation suitable. ### Children (1-12 years) - **Acute Otitis Media (AOM)**: - **Dose**: **5 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: **200 mg** per dose (400 mg daily) - **Pharyngitis/Tonsillitis**: - **Dose**: **5 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: **100 mg** per dose (200 mg daily) - **Uncomplicated Urinary Tract Infections**: - **Dose**: **5 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: **100 mg** per dose (200 mg daily) - **Special Notes**: Total daily dose should not exceed adult maximums. Oral suspension or tablets available. ### Adolescents (13-18 years) - **Dose**: Use **adult dosing** recommendations. - **Maximum**: Adult maximum dose applies. ## Safety Information ### Contraindications - **Absolute**: Known hypersensitivity to cefpodoxime. - **Absolute**: Known hypersensitivity to other cephalosporin antibiotics. - **Relative**: History of severe immediate hypersensitivity reaction to penicillin (due to potential cross-reactivity). ### Common Adverse Effects - **Common (1-10%)**: Diarrhea, nausea, vomiting, abdominal pain, headache, rash, vaginitis. - **Serious but Rare**: Clostridioides difficile-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis, SJS, TEN), blood dyscrasias (e.g., thrombocytopenia, leukopenia). ### Key Drug Interactions - **Antacids, H2-receptor antagonists (e.g., ranitidine), PPIs (e.g., omeprazole)**: May decrease cefpodoxime absorption. - **Effect and clinical significance**: Reduced bioavailability of cefpodoxime. - **Monitoring requirement**: Administer cefpodoxime 2-3 hours before or after these agents. - **Probenecid**: May increase cefpodoxime plasma concentrations. - **Effect and clinical significance**: Inhibits renal excretion of cefpodoxime. - **Oral Anticoagulants (e.g., warfarin)**: May increase INR and bleeding risk. - **Monitoring requirement**: Closely monitor INR and signs of bleeding. ## Monitoring & Follow-up - **Before Treatment**: Assess patient allergy history (especially to penicillins/cephalosporins). - **During Treatment**: Monitor for resolution of infection symptoms. - **During Treatment**: Monitor for signs of superinfection, especially severe diarrhea (C. difficile). - **During Treatment**: Monitor renal function in patients with renal impairment. - **Clinical Signs**: Watch for rash, hives, difficulty breathing, or severe abdominal pain with bloody diarrhea. ## Clinical Pearls - 💡 **Tip 1**: Administer cefpodoxime **with food** to enhance absorption and minimize GI upset. - 💡 **Tip 2**: Cefpodoxime oral suspension **must be shaken well** before each use. - 💡 **Tip 3**: Refrigerate the oral suspension and discard any unused portion after **14 days**. - 💡 **Tip 4**: Not active against Methicillin-Resistant Staphylococcus aureus (MRSA). > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.